DIAGNOS Announces Licensing Deal With Inb al Haythem Center in Algeria

BROSSARD, QUEBEC--(Marketwired - May 4, 2015) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a licensing deal with Inb al Haythem Center in Algeria.

Inb al Haythem Center provides contact lenses and ophthalmic surgery in Algiers, Algeria. DIAGNOS will be providing its proprietary telemedicine software, CARA, and automated retina image interpretation in order to help optimize the clinic's existing retina screening services.

"Inb al Haythem Center offers a multitude of services related to ophthalmology and already owns all of the equipment required for retina screening. Recognizing the utility of CARA and the retinal analysis services DIAGNOS provides, the clinic has already committed to two years with the platform and automated grading. DIAGNOS will integrate CARA with the clinic's existing infrastructure, providing a seamless transition," said Dr. Hadi Chakor, DIAGNOS' Algeria Country Manager.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.